292 related articles for article (PubMed ID: 28198434)
21. Copy-number and gene dependency analysis reveals partial copy loss of wild-type SF3B1 as a novel cancer vulnerability.
Paolella BR; Gibson WJ; Urbanski LM; Alberta JA; Zack TI; Bandopadhayay P; Nichols CA; Agarwalla PK; Brown MS; Lamothe R; Yu Y; Choi PS; Obeng EA; Heckl D; Wei G; Wang B; Tsherniak A; Vazquez F; Weir BA; Root DE; Cowley GS; Buhrlage SJ; Stiles CD; Ebert BL; Hahn WC; Reed R; Beroukhim R
Elife; 2017 Feb; 6():. PubMed ID: 28177281
[TBL] [Abstract][Full Text] [Related]
22. Investigating the Molecular Mechanism of H3B-8800: A Splicing Modulator Inducing Preferential Lethality in Spliceosome-Mutant Cancers.
Spinello A; Borišek J; Malcovati L; Magistrato A
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681880
[TBL] [Abstract][Full Text] [Related]
23. Cancer-associated SF3B1 mutants recognize otherwise inaccessible cryptic 3' splice sites within RNA secondary structures.
Kesarwani AK; Ramirez O; Gupta AK; Yang X; Murthy T; Minella AC; Pillai MM
Oncogene; 2017 Feb; 36(8):1123-1133. PubMed ID: 27524419
[TBL] [Abstract][Full Text] [Related]
24. Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B.
Kashyap MK; Kumar D; Villa R; La Clair JJ; Benner C; Sasik R; Jones H; Ghia EM; Rassenti LZ; Kipps TJ; Burkart MD; Castro JE
Haematologica; 2015 Jul; 100(7):945-54. PubMed ID: 25862704
[TBL] [Abstract][Full Text] [Related]
25. Interchangeable SF3B1 inhibitors interfere with pre-mRNA splicing at multiple stages.
Effenberger KA; Urabe VK; Prichard BE; Ghosh AK; Jurica MS
RNA; 2016 Mar; 22(3):350-9. PubMed ID: 26742993
[TBL] [Abstract][Full Text] [Related]
26. Cyclin-dependent kinase 1 (CDK1) and CDK2 have opposing roles in regulating interactions of splicing factor 3B1 with chromatin.
Murthy T; Bluemn T; Gupta AK; Reimer M; Rao S; Pillai MM; Minella AC
J Biol Chem; 2018 Jun; 293(26):10220-10234. PubMed ID: 29764937
[TBL] [Abstract][Full Text] [Related]
27. Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.
Brierley CK; Steensma DP
Curr Hematol Malig Rep; 2016 Dec; 11(6):408-415. PubMed ID: 27492253
[TBL] [Abstract][Full Text] [Related]
28. Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors.
Scott LM; Rebel VI
J Natl Cancer Inst; 2013 Oct; 105(20):1540-9. PubMed ID: 24052622
[TBL] [Abstract][Full Text] [Related]
29. Novel antitumour indole alkaloid, Jerantinine A, evokes potent G2/M cell cycle arrest targeting microtubules.
Raja VJ; Lim KH; Leong CO; Kam TS; Bradshaw TD
Invest New Drugs; 2014 Oct; 32(5):838-50. PubMed ID: 24927857
[TBL] [Abstract][Full Text] [Related]
30. AI-assisted proofreading of RNA splicing.
Guerra-Moreno Á; Valcárcel J
Genes Dev; 2023 Dec; 37(21-24):945-947. PubMed ID: 38092520
[TBL] [Abstract][Full Text] [Related]
31. A Comprehensive Overview of Structure-Activity Relationships of Small-Molecule Splicing Modulators Targeting SF3B1 as Anticancer Agents.
Zhang D; Meng F
ChemMedChem; 2020 Nov; 15(22):2098-2120. PubMed ID: 33037739
[TBL] [Abstract][Full Text] [Related]
32. Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
Pellagatti A; Boultwood J
Adv Biol Regul; 2017 Jan; 63():59-70. PubMed ID: 27639445
[TBL] [Abstract][Full Text] [Related]
33. The spliceosome as a target of novel antitumour drugs.
Bonnal S; Vigevani L; Valcárcel J
Nat Rev Drug Discov; 2012 Nov; 11(11):847-59. PubMed ID: 23123942
[TBL] [Abstract][Full Text] [Related]
34. SF3B1 mutation in pancreatic cancer contributes to aerobic glycolysis and tumor growth through a PP2A-c-Myc axis.
Yang JY; Huo YM; Yang MW; Shen Y; Liu DJ; Fu XL; Tao LY; He RZ; Zhang JF; Hua R; Jiang SH; Sun YW; Liu W
Mol Oncol; 2021 Nov; 15(11):3076-3090. PubMed ID: 33932092
[TBL] [Abstract][Full Text] [Related]
35. Nonsense-Mediated RNA Decay Is a Unique Vulnerability of Cancer Cells Harboring
Cheruiyot A; Li S; Nonavinkere Srivatsan S; Ahmed T; Chen Y; Lemacon DS; Li Y; Yang Z; Wadugu BA; Warner WA; Pruett-Miller SM; Obeng EA; Link DC; He D; Xiao F; Wang X; Bailis JM; Walter MJ; You Z
Cancer Res; 2021 Sep; 81(17):4499-4513. PubMed ID: 34215620
[TBL] [Abstract][Full Text] [Related]
36. A genome-wide siRNA screen for regulators of tumor suppressor p53 activity in human non-small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatment.
Siebring-van Olst E; Blijlevens M; de Menezes RX; van der Meulen-Muileman IH; Smit EF; van Beusechem VW
Mol Oncol; 2017 May; 11(5):534-551. PubMed ID: 28296343
[TBL] [Abstract][Full Text] [Related]
37. Pan-cancer analysis identifies mutations in
Liu Z; Zhang J; Sun Y; Perea-Chamblee TE; Manley JL; Rabadan R
Proc Natl Acad Sci U S A; 2020 May; 117(19):10305-10312. PubMed ID: 32332164
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological inhibition of the spliceosome subunit SF3b triggers exon junction complex-independent nonsense-mediated decay.
Carvalho T; Martins S; Rino J; Marinho S; Carmo-Fonseca M
J Cell Sci; 2017 May; 130(9):1519-1531. PubMed ID: 28302904
[TBL] [Abstract][Full Text] [Related]
39. The cryo-EM structure of the SF3b spliceosome complex bound to a splicing modulator reveals a pre-mRNA substrate competitive mechanism of action.
Finci LI; Zhang X; Huang X; Zhou Q; Tsai J; Teng T; Agrawal A; Chan B; Irwin S; Karr C; Cook A; Zhu P; Reynolds D; Smith PG; Fekkes P; Buonamici S; Larsen NA
Genes Dev; 2018 Feb; 32(3-4):309-320. PubMed ID: 29491137
[TBL] [Abstract][Full Text] [Related]
40. The development and application of small molecule modulators of SF3b as therapeutic agents for cancer.
Webb TR; Joyner AS; Potter PM
Drug Discov Today; 2013 Jan; 18(1-2):43-9. PubMed ID: 22885522
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
